Hi, this is Theresa Agnew, CEO of BioGaia, and we are here to present our Q1 2026 results. In terms of the highlights, we have growth excluding currency effects of 15%. Our EBIT margin for the quarter is 27%. And overall, our free cash flow is 67 million SEK.
Our net sales reached 373 million SEK.
And as I said, organic growth of 15%. 2% growth when you include currency effects. Our Asia Pacific region increased by 6%, excluding currency effects. In the Americas, we increased by 12%, excluding currency effects. And for Europe, Middle East, and Africa, we increased by 24%, excluding currency effects.
Our operating profit for the quarter was around 101 million SEK, which is 4% growth.
And our EBIT margin, as I said, was 27%, compared to 27% for the same quarter last year.
To remind you of our company strategy. We have three strategic pillars. Grow the Core, where we focus on growing our core health areas. Gut health, of which colic is a part. Oral health and immune health.
Our second strategic pillar is what we call expansion through direct markets. So focusing on growing our current 12 direct markets and focusing our marketing and selling and investment activities in those markets to drive growth ahead of market. And our third strategic pillar is what we call breakthrough innovation, where we work on new products that are in new areas.
So new market creation opportunities for probiotics.
And our foundations are, of course, our people and our culture investing for profitable growth, using digital as an enabler of the business, both in how we go to market in our omnichannel approach, as well as how we digitize internally to make us more productive and efficient, driven by science, which has been a foundation for us for over 35 years, and sustainable solutions. How are we delivering on our strategy in terms of grow the core for the quarter? We are driving growth in both the pediatric and adult segments. We are investing, as I said, in marketing and selling activities to drive strong double-digit growth in direct markets.
We're continuing the rollout of new products.
We launched a new product, BioGaia Gastrus Pure Action, in Finland originally in October 2024, and now we have rolled it out to approximately 12 markets, and it is now the third highest growth contributor to our overall business in terms of million SEK for a second quarter in a row. It was our third largest growth contributor in Q4 and again now in Q1 2026.
And we are also rolling out a new product, BioGaia Prodentis Fresh Breath, which launched last year in Q3.
And we continue to roll that out into more markets. In terms of expansion through direct markets, we launched Germany and Austria earlier in Q1, and that is doing really well with strong growth ahead of our plan. France and Canada actually had record sales in Q1. So both of those direct markets are doing very strongly. And then US continues in Q1 with its strong double-digit growth trend. So direct markets performing extremely well in the Breakthrough Innovation area, we have our BioGaia New Sciences Focus, which is on skin health.
And we continue to roll out our probiotic ointment to more and more countries around the world. And we have some exciting news to announce a new product launch in our pediatrics area. This is our next-generation patented probiotic baby drops, which is, as you know, a dual-strain product.
This is our next generation patented probiotic baby drops, which I think as you know, this is a dual strain product.
So this contains our original Protectis strain, which is DSM 17938. And a new patented strain, which we call BGR 46. Our current Protectis drops will remain available in the market. So this will be an additional product launch which will round out our premium portfolio in terms of baby drops. We just completed a clinical study where we achieved positive results both in efficacy and safety. So we will be writing a manuscript and submitting this for publication. So with this product, we get the benefit of additive probiotic effects. So it's supported by numerous preclinical studies that have been published, such as the survival and activity in a bile-rich environment, which is very important for bacteria to survive.
The BGR 46 also increases melatonin induction in the intestinal cells. So this is a really positive differentiator in this strain. This new strain also has higher production levels of anti-inflammatory compounds such as adenosine, and this new strain is even better adapted to the infant gut in a milk-rich environment. So there are a number of things that we've studied preclinically about this new strain, BGR 46, which provide additive probiotic effects. But as I said, this is a new product that will be available in addition to our original BioGaia Protectis drops.
Our first launch is actually this week in the UK.
And then we will follow with additional rollouts by market over this year and into next year. So, very exciting news for us in terms of a new product launch.
Our next-generation probiotic drops, in addition to other launches, were introduced in the quarter. As always, alongside our existing product portfolio, we talk about other launches as we expand into new countries. So, just a couple of examples. We launched our Prodentis Fresh Breath lozenges in Sweden and Germany. Of course, we launched some new products in the quarter as we started our direct market presence in the quarter. Also, Prodentis Fresh Breath lozenges launched in the UK and Finland in this quarter. Malaysia launched our BioGaia Skincare Probiotic ointment. So, a number of other product launches occurred within the quarter, alongside some of the other key events.
We had quite a bit of news in the quarter.
On February 3rd, we announced that our fourth quarter would exceed market expectations. In February, we signed a renewed distribution agreement with a long-standing partner, Ewopharma. And they cover Central and Eastern Europe as well as Switzerland.
For us, on March 17th, we also announced exercising the option to acquire the remaining 20% of the shares in Nutraceutics, which is our company in the United States.
On March 20th, we announced an exciting clinical study publication. It's a ten-year follow-up study from when infants were given our Protectis drops. And we saw that there was a markedly lower prevalence of functional abdominal pain in these children after they had received our drops in the first three months of life. And then finally, at the end of April, we also published new scientific findings around our patented LongevityGuard technology, which is our desiccant strip that goes into our drops products as well as our probiotic ointment to improve the stability and extend the shelf life of our probiotics to 24 months.
So a lot of interesting, exciting news that we had during the quarter in terms of growth as we look at it across our segments.
You can see the past growth by quarter.
So in pediatrics for Q1, we grew by 13% excluding currency effects. And in the adult segment we grew by 18% excluding currency effects.
In pediatrics, we saw very high sales in the US and also France in the quarter. And in adults, we saw very high sales in EMEA, Asia Pacific, and we saw strong growth in South Africa as well as Japan.
In addition, looking at our Pediatrics segment for the quarter, we grew 13% excluding currency effects. Adult health, we grew 18% excluding currency effects. So strong growth for both segments. And currently for the quarter, 73% of our sales are in the pediatric segment.
In terms of our regional sales, I highlighted this in the beginning. EMEA grew 24% excluding currency effects. Asia Pacific grew 6% and Americas grew 12%. With EMEA, we saw strong growth in both the Pediatrics and Adult segments.
In Asia Pacific, we saw strong growth in Japan and Australia.
Our direct markets in Asia Pacific also saw strong growth.
Sales for the quarter were negatively impacted by some quarterly variations that we saw for China between Q4 and Q1 and in the Americas. As I said, we saw 12% growth excluding currency effects, with strong growth in the US and Canada and growth in the quarter also strong for both the Pediatrics segment and the Adult Health segment. Now I will turn it over to Alex to go through the financials in some more detail.